-
Citing ‘capacity constraints,’ Novo Nordisk plots global wind-down of human insulin pen production
By Fraiser Kansteiner Nov 14, 2024 2:13pm As sales of Novo Nordisk’s GLP-1 drugs for diabetes and […]
November 2024
Archive
Categorise
Recent Posts
- Citing ‘capacity constraints,’ Novo Nordisk plots global wind-down of human insulin pen production
- NIH, MSKCC researchers publish AI model for predicting immunotherapy responses
- ASCO: Replacing chemotherapy with ADCs? AbbVie rebuilds next-gen assets after Rova-T flop
- Prediction: These Could Be the Best-Performing Pharmaceutical Stocks Through 2030
- 8 Biotech Companies in Chicago Cultivating the City’s Life Sciences Scene
